Literature DB >> 2435809

A solid-phase anti-C3 assay for detection of immune complexes in six distinguished forms.

K Iida, K Mitomo, T Fujita, N Tamura.   

Abstract

A solid-phase anti-C3 assay detecting immune complexes associated with C3 fragments is described. Two monoclonal antibodies against C3 fragments are used; one recognizes an epitope expressed on C3b, C3c and C3i, the other recognizes an epitope expressed on C3dg and iC3b. Combining these monoclonal anti-C3s with antibodies against class-specific immunoglobulins in enzyme-linked immunosorbent assay (ELISA), immune complexes (ICs) are detected in six distinguished forms; C3b-IgG-IC, iC3b/C3dg-IgG-IC, C3b-IgA-IC, iC3b/C3dg-IgA-IC, C3b-IgM-IC and iC3b/C3dg-IgM-IC. About three-fourths of the plasma samples from patients with active SLE or IgA-nephritis were found positive in one or more types of ICs. IgA-type ICs were found very frequently in patients with autoimmune or renal diseases.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2435809     DOI: 10.1016/0022-1759(87)90431-5

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

1.  C3-containing serum immune complexes in patients with systemic lupus erythematosus: correlation to disease activity and comparison with other rheumatic diseases.

Authors:  C Huber; A Rüger; M Herrmann; F Krapf; J R Kalden
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

2.  Characterization of three monoclonal antibodies against C3 with selective specificities.

Authors:  K Iida; K Mitomo; T Fujita; N Tamura
Journal:  Immunology       Date:  1987-11       Impact factor: 7.397

3.  Complement Receptor 2 Based Immunoassay Measuring Activation of the Complement System at C3-Level in Plasma Samples From Mice and Humans.

Authors:  Lene Halkjær; Anne Troldborg; Henrik Pedersen; Lisbeth Jensen; Annette Gudmann Hansen; Troels Krarup Hansen; Mette Bjerre; Jakob Appel Østergaard; Steffen Thiel
Journal:  Front Immunol       Date:  2020-05-05       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.